Isolated Progression of NSCLC on Immunotherapy – OncLive
OncLive |
Isolated Progression of NSCLC on Immunotherapy
OncLive Naiyer Rizvi, MD: One point I'd like to make, which I think is really important for physicians using these drugs, is that response evaluations can be very complex. And agreed, pseudo progression is not common, so I wouldn't necessarily worry about that. |
